NamibiaTuberculosis profile
Population  2017 2.5 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.75 (0.48–1.1) 30 (19–43)
Mortality (HIV+TB only) 0.8 (0.55–1.1) 31 (22–43)
Incidence  (includes HIV+TB) 11 (8.2–14) 423 (324–535)
Incidence (HIV+TB only) 3.9 (2.5–5.5) 153 (99–219)
Incidence (MDR/RR-TB)** 0.95 (0.65–1.3) 37 (26–51)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.88 (0.81–0.94) 3.6 (3.1–4.1) 4.4 (3.7–5.2)
Males 0.92 (0.85–0.99) 5.4 (4.4–6.3) 6.3 (5.1–7.5)
Total 1.8 (1.6–2) 8.9 (6.9–11) 11 (8.2–14)
TB case notifications, 2017  
Total cases notified 8 855
Total new and relapse 8 575
          - % tested with rapid diagnostics at time of diagnosis 100%
          - % with known HIV status 98%
          - % pulmonary 82%
          - % bacteriologically confirmed among pulmonary 83%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.15 (0.1–0.2)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 3 139 36%
          - on antiretroviral therapy 3 021 96%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  470
(410–540)
Estimated % of TB cases with MDR/RR-TB 5% (4.1–5.9) 12% (9.4–14)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs   78
Laboratory-confirmed cases MDR/RR-TB: 409, XDR-TB: 14
Patients started on treatment **** MDR/RR-TB: 410, XDR-TB: 13
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 84% 8 857
Previously treated cases, excluding relapse, registered in 2016 68% 297
HIV-positive TB cases registered in 2016 80% 3 410
MDR/RR-TB cases started on second-line treatment in 2015 74% 288
XDR-TB cases started on second-line treatment in 2015 0% 2
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 15%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
34% (31–37)
TB financing, 2018  
National TB budget (US$ millions) 49
Funding source: 57% domestic, 3% international, 40% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-11-14 Data: www.who.int/tb/data